Medical Treatment of Disorders of Bone Metabolism in Patients with Vitamin-D-Dependent Rickets Type I
Objective is to determine the effects of medical therapy of genetically caused disorders of bone metabolism in patients with vitamin-D-dependent rickets (VDDR) type I. Materials and methods. On the basis of a consultative and outpatient department of SI «Institute of Traumatology and Orthopaedy of NAMSU» 48 patients with VDDR type I were observed and treated. Medical treatment of patients with rickets was performed in 4 steps. Stage 1 consisted of a full examination of the patient, including serum calcium, serum phosphorus, urine tests, determination of calcidiol and serum calcitriol, indicators of parathyroid hormone and osteocalcin, as well as a marker of bone formation P1NP and osteoresorbtion B-CTx. At the first stage, without fail, a genetic test was performed in the children to detect changes (polymorphisms) in alleles of receptors to vitamin D and type I collagen. At the next stages the survey was conducted in its entirety, except for genetic research. Results. Comprehensive study of vitamin D metabolism and biochemical indices of vital activity of bone tissue in patients with VDDR type 1 allowed come close to understanding of some issues of pathogenesis and nature of osteomalation changes and in future of osteoporotic changes on different levels, to objectify these changes in relevant indicators of biochemical research and, depending on changes, develop different schemes of medical treatment of this disease. Conclusion. For medical treatment of VDDR1 alfacalcidol is a drug of choice because it could be transformed by the liver into calcitriol, passing genetically damaged renal 1α hydroxylation. On the basis of biochemical indices in patients with vitamin-D-depended rickets type 1 pathogeneticall substantiated rational effective drug therapy of orthopedic manifestations that includes cholecalciferol (80.000 U per month) and alfacalcidol (7.5 mg per month). The proposed treatment provides significant improvement in bone metabolіsm by biochemical and clinical indicators after the first month of three-month treatment (p < 0.05).
Full Text:PDF (Українська)
Гук Ю.М., Марциняк С.М., Кінча-Поліщук Т.А., Зотя А.В. Метаболізм кісткової тканини у хворих на вітамін-D-залежний рахіт 1-го типу // Вісник ортопедії, травматології та протезування. — 2015. — Т. 84, № 1. — С. 65-69.
Alzahrani A.S. A novel G102E mutation of CYP27B1 in a large family with vitamin D-dependent rickets type 1 / Alzahrani A.S, Zou M., Baitei E.Y. [et al.] // J. Clin. Endocrinol. Metab. — 2010. — P. 128-145.
Brooks M.H. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D / Brooks M.H., Bell N.H., Love L. [et al.] // New England J. Med. — 1978. — Vol. 298. — P. 996-999.
Econs M.J. Bone disease resulting from inherited disorders of renal tubule transport and vitamin D metabolism // Disorders of Bone and Mineral Metabolism / Ed. by F.L. Coe, M.J. Favus, M.J. Econs, M.K. Drezner. — New York: Raven Press, 1992. — Р. 935-950.
Fu G.K., Portale A.A., Miller W.L. Complete structure of the human gene for the vitamin D 1α-hydroxylase, P450c1α // DNA Cell Biol. — 1997.
Holick M.F. The use and interpretation of assays for vitamin D and its metabolites / M.F. Holick // J. Nutr. — 1990. — 120(Suppl. 11). — P. 1464-1469.
Katavetin P. A girl with a novel splice site mutation in VDR supports the role of a ligand-independent VDR function on hair cycling / Katavetin P., Wacharasindhu S., Shotelersuk V. // Horm. Res. — 2006. — P. 332-368.
Kimmel-Jehan C., De Luca H.F.Cloning of the mouse 25-hydroxyvitamin D3 1α-hydroxylase (CYP1α) gene // Biochim. Biophys. Acta. — 2000.
Kitanaka S., Takeyama K., Murayama A. et al. Inactivaiting mutations in the 25-hydroxyvitamin D3 1α-hydroxylase gene in patients with pseudovitamin D-deficiency rickets // N. Engl. J. Med. — 1998.
Panda D.K., Al Kawas S., Seldin M.F., Hendy G.N., Goltzman D. 25-hydroxyvitamin D 1alpha-hydroxylase: structure of the mouse gene, chromosomal assignment, and developmental expression // J. Bone Miner. Res. — 2001.
Silver J. Vitamin D-dependent rickets types I and II. Diagnosis and response to therapy / Silver J., Landau H., Bab I. [et al.] // Israel J. Med. Sci. — 1985. — Vol. 21. — P. 53-56.
Tohme J.F. Biochemical markers of bone metabolism / Tohme J.F., Seibel M.J., Silverberg S. J. [et al.] // Zietschr. Rheumatol. — 1991. — Vol. 50. — P. 133-141.
Yoshida T., Monkawa T., Tenenhouse H.S. et al. Two nowel 1α-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type 1 // Kidney Int. — 1998.
Copyright (c) 2016 TRAUMA
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2018